Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Talin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Talin. Methods of using these compounds for modulation of Talin expression and for treatment of diseases associated with expression of Talin are provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-2. Methods of using these compounds for modulation of SRC-2 expression and for treatment of diseases associated with expression of SRC-2 are provided.

Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecule, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.

Abstract: A spike tissue-specific promoter has been isolated, sequenced and tested. The promoter can be used to make gene constructs including a protein-coding sequence not natively associated with the promoter and a sufficient portion of the promoter such that the portion actuates the preferential expression of the protein-coding sequence in the spike tissue of cereal grain plants.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases and conditions associated with expression of PTEN are provided. Such conditions include diabetes and hyperproliferative conditions. Methods for decreasing blood glucose levels, inhibiting PEPCK expression, decreasing blood insulin levels, decreasing insulin resistance, increasing insulin sensitivity, decreasing blood triglyceride levels or decreasing blood cholesterol levels in an animal using the compounds of the invention are also provided. The animal is preferably a human; also preferably the animal is a diabetic animal.

Abstract: Macromolecules are provided that have increased nuclease resistance, increasing binding affinity to a complementary strand, and that activate RNase H enzyme. The macromolecules have the structure PNA-DNA-PNA where the DNA portion is composed of subunits of 2′-deoxy-erythro-pento-furanosyl nucleotides and the PNA portions are composed of subunits of peptide nucleic acids. Such macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to therapeutics.

Abstract: The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which target bacteria at different stages of the bacterial life cycle, which are delivered alone or in combination to bacteria or bacteria-infected cells. The invention relates to toxic agents which are lethal to diseased cells and methods for targeting such toxic agents to a diseased cell in order to treat and/or eradicate the disease. The present invention relates to promoter elements which are pathogen-specific or tissue-specific and the use of such promoter elements to achieve pathogen-specific or tissue-specific expression of the toxic agent(s) and/or ribozyme(s) of the present invention.

Abstract: Novel compounds that mimic and/or modulate the activity of wild-type nucleic acids. In general, the compounds contain a selected sequence of nucleosidic bases or other reactive groups that are covalently bound through nitrogen-containing linear, hairpin, dumbbell, and circular shaped tethers.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ubiquitin protein ligases WWP1 and WWP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ubiquitin protein ligases WWP1 and WWP2. Methods of using these compounds for modulation of ubiquitin protein ligases WWP1 and WWP2 expression and for treatment of diseases associated with expression of ubiquitin protein ligases WWP1 and WWP2 are provided.

Abstract: Methods for detecting the presence or absence of an analyte in a sample are disclosed. Kits for performing the analysis methods of the invention are also disclosed.

Abstract: A composition comprises a glucocorticoid receptor agonist and a compound which decreases levels of active human serine/threonine protein phosphatase 5 protein in cells. The glucocorticoid receptor agonist is dexamethasone and the compound is an antisense oligonucleotide of about 8 to 50 nucleotides in length which is targeted to a nucleic acid encoding human serine/threonine protein phosphatase 5. The composition is useful in a method of enhancing glucocorticoid activity, and in a method of enhancing the inhibition of hyperproliferation of cells where the inhibition is by contacting the cells with a compound which decreases levels of active human serine/threonine protein phosphatase 5 protein in cells. The compound is thus useful to enhance glucocorticoid therapy and to enhance inhibition of hyperproliferation relating to PP5.

Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr; (TNF-&agr;). Antisense oligonucleotides targeted to nucleic acids encoding TNF-&agr; are preferred. Methods of using these oligonucleotides for inhibition of TNF-&agr; expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-&agr; are provided.

Abstract: This invention provides cDNA encoding a prostate-cancer specific marker, Repro-PC-1.0, Repro-PC-1.0 polypeptides and methods for use in diagnosis and therapy.

Abstract: A human protein termed CIF150/hTAFII150 recognizes and selects TATA-less core promoters for cell cycle specific genes. Thus, CIF150/hTAFII150 plays an important and selective role in establishing gene expression patterns necessary for progression through the cell cycle. The CIF150/hTAFII150 gene and its expression products can be used to alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell and to treat disorders involving alterations in the regulation of mitosis or cell cycle progression.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of hnRNP A1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hnRNP A1. Methods of using these compounds for modulation of hnRNP A1 expression and for treatment of diseases associated with expression of hnRNP A1 are provided.

Abstract: Methods and compositions for the inactivation and removal of contaminants of a biological composition are disclosed. The methods include the steps of: (a) contacting the biological composition with an inactivating agent including an aziridino moiety, such as ethyleneimine, an oligomer of ethyleneimine, or a haloderivative salt of either ethyleneimine or an oligomer of ethyleneimine, where a portion of the agent reacts with and inactivates the contaminant, and a portion of the agent remains unreacted; (b) contacting the product of step (a) with a lipophilic quenching agent including at least one quenching moiety attached to a lipophilic moiety, under conditions and for a time sufficient to allow the unreacted agent to bond covalently to the quenching moiety; and (c) separating the lipophilic quenching agent and the quenched inactivating agent from the biological composition.